Quality of life аssessment in patients with pulmonary arterial hypertension
https://doi.org/10.38109/2075-082X-2024-3-41-46
Abstract
Pulmonary arterial hypertension (PAH) is a severe progressive disease with a pure prognosis, which symptoms have a negative impact on patient's quality of life (QoL). Due to the implementation of new effective PAH-specific drugs, currently the task of therapy is not only to prolong the patient's life, but also to improve its quality. The term "QoL" combines information about the main areas of human life: psychological, social, physical and mental well-being. A set of laboratory and instrumental tests is being used to diagnose PAH, but they cannot characterize indicators of QoL. The main tool for studying QoL is a questionnaire. Questionnaires for assessing QoL can be divided into two groups: universal (general) and special (disease-specific). general questionnaires are used to study QoL both in healthy people and in various diseases. Special questionnaires contain specific components for a particular disease, and therefore must be the most sensitive. The first studies of QoL in patients with PAH showed significant disorders in all areas of patients' lives. Currently, many randomized controlled trials of the efficacy of PAH-specific therapy study QoL using various questionnaires as a secondary end-point. SF-36 and EuroQol-5D are used the most commonly among the general questionnaires. Special questionnaires have been developed and validated to assess QoL in patients with PAH relatively recently. Each questionnaire has its advantages and disadvantages. In this review we will consider the possibilities of assessing QoL in patients with PAH using universal (SF-36, EuroQol-5D) and disease-specific for PAH (CAMPHOR, PAH-SYMPACT, EmPHasis-10) questionnaires. These questionnaires have proven to be a valuable instrument in scientific and clinical practice, which is emphasized in actual 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Currently it is of interest to study the relationship between the results of QoL questionnaires and clinical, laboratory and instrumental tests.
Keywords
pulmonary arterial hypertension,
quality of life,
quality of life questionnaire,
SF-36,
EQ-5D,
CAMPHOR,
PAH-SYMPACT,
EmPHasis-10
Supporting agencies: The work was carried out without attracting additional funding from third parties
About the Authors
E. A. Nikolaeva
E.I. Chazov National Medical Research Center of cardiology
Russian Federation
Russian Federation
Elena A. Nikolaeva, cardiologist
Scientific research A.L. Myasnikov Institute of Clinical Cardiology; Department of the organization of quality control of medical care and examination of temporary disability
121552; St. Academician Chazova, 15 a; Moscow
tel.: 8-495-414-65-42
Z. S. Valieva
E.I. Chazov National Medical Research Center of cardiology
Russian Federation
Russian Federation
Zarina S. Valieva, Dr. Of Sci. (Med.), Senior Researcher
A.L. Myasnikov Institute of Clinical Cardiology; Department of Pulmonary Hypertension and Heart Diseases
121552; St. Academician Chazova, 15 a; Moscow
tel.: 8-495-414-66-30,
T. V. Martynyuk
E.I. Chazov National Medical Research Center of cardiology; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tamila V. Martynyuk, Dr. Of Sci. (Med.), Head of the Department, Professor
A.L. Myasnikov Institute of Clinical Cardiology; Department of Pulmonary Hypertension and Heart Diseases; Faculty of Continuing Professional Education; Department of Cardiology
121552; St. Academician Chazova, 15 a; 117513; 1 bldg. 6 Ostrovityanova St.; Moscow
tel.: 8-495-414-64-50
References
1. Chazova I.E., Martynyuk T.V., Shmalts A.A., Gramovich V.V., Danilov N.M., Veselova T.N., Korobkova I.Z., Sarybaev A.Sh., Stukalova O.V., Azizov V.A., Barbarash O.L., Galyavich A.S., Gorbachevsky S.V., Medvedeva E.A., Matchin Yu.G., Mukarov M.A., Nakonechnikov S.N., Filippov E.V., Chernogrivov I.E. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023). Eurasian heart journal. 2024;(1):6-85. (In Russ.).] doi: 10.38109/2225-1685-2024-1-6-85
2. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas g, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. Erratum in: Eur Heart J. 2023 Apr 17;44(15):1312. PMID: 36017548. doi: 10.1093/eurheartj/ehac237
3. Pulmonary hypertension / Edited by I.E. Chazova and T.V. Martynyuk. – M.: Praktika, 2015. – 928 p. (In Russ.)
4. Novik A.A., Ionova T.I. Handbook of Quality of Life Research in Medicine (4<sup>th</sup> edition, revised and supplemented)/ Ed. Academician of the Russian Academy of Sciences Yu.L. Shevchenko. Moscow: Publishing house of the National Medical and Surgical Center named after N.I. Pirogov, 2021. (In Russ.)
5. Makarova E.I., Yagudina R.I. Methodology of calculation of qaly in pharmacoeconomic modelling: using questionnaires of study of patient’s quality of life. Pharmacoeconomics: theory and practice. 2018;6(1):4-9. (In Russ.). doi: 10.30809/phe.1.2018.1
6. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2004 Nov;126(5):1452-9. doi: 10.1378/chest.126.5.1452. PMID: 15539712.
7. Instructions for processing data obtained with the SF-36 questionnaire. (In Russ.). http://bono-esse.ru/blizzard/RPP/sf36.pdf
8. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau g, Rubin LJ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Dec 16;52(25):2127-34. PMID: 19095129. doi: 10.1016/j.jacc.2008.08.059
9. Mathai SC, Suber T, Khair RM, Kolb TM, Damico RL, Hassoun PM. Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2016 Jan;13(1):31-9. PMID: 26492065; PMCID: PMC4722843. doi: 10.1513/AnnalsATS.201412-572OC
10. Jansa P, Pulido T. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial. Am J Cardiovasc Drugs. 2018 Feb;18(1):1-11. PMID: 29280064; PMCID: PMC5772137. doi: 10.1007/s40256-017-0260-1
11. EuroQol group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. PMID: 10109801. doi: 10.1016/0168-8510(90)90421-9
12. Amirdjanova V.N., Erdes S.F. Validation of general questionnaire EuroQol-5D (EQ-5D) Russian version. Rheumatology Science and Practice. 2007;45(3):69-76. (In Russ.). doi: 10.14412/1995-4484-2007-691
13. Olschewski H, Simonneau G, galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely Dg, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W; Aerosolized Iloprost Randomized Study group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 1;347(5):322-9. PMID: 12151469. doi: 10.1056/NEJMoa020204
14. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25;369(4):330-40. PMID: 23883378. doi: 10.1056/NEJMoa1209655
15. Hoeper MM, Simonneau g, Corris PA, ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017 Sep 9;50(3):1602425. PMID: 28889107; PMCID: PMC5898946. doi: 10.1183/13993003.02425-2016
16. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006 Feb;15(1):103-15. PMID: 16411035. doi: 10.1007/s11136-005-3513-4
17. Reis A, Santos M, Vicente M, Furtado I, Cruz C, Melo A, Carvalho L, Gonçalves F, Sa-Couto P, Almeida L. Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study. Biomed Res Int. 2018 Mar 19;2018:3924517. PMID: 29750153; PMCID: PMC5884279. doi: 10.1155/2018/3924517
18. Yorke J, Corris P, gaine S, gibbs JS, Kiely Dg, Harries C, Pollock V, Armstrong I. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014 Apr;43(4):1106-13. Epub 2013 Nov 14. PMID: 24232702; PMCID: PMC3971119. doi: 10.1183/09031936.00127113
19. Favoccia C, Kempny A, Yorke J, Armstrong I, Price LC, McCabe C, Harries C, Wort SJ, Dimopoulos K. EmPHasis-10 score for the assessment of quality of life in various types of pulmonary hypertension and its relation to outcome. Eur J Prev Cardiol. 2019 Aug;26(12):1338-1340. Epub 2018 Dec 19. PMID: 30567456. doi: 10.1177/2047487318819161
20. Lewis RA, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A, Church AC, Coghlan JG, Davies RJ, Dimopoulos K, Elliot C, Gibbs JSR, gin-Sing W, Haji G, Hameed Ag, Howard LS, Johnson MK, Kempny A, Kiely Dg, Lo Giudice F, McCabe C, Peacock AJ, Peleyeju O, Pepke-Zaba J, Polwarth G, Price L, Sabroe I, Schreiber BE, Sheares K, Taboada D, Thompson AAR, Toshner MR, Wanjiku I, Wort SJ, Yorke J, Condliffe R. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. Eur Respir J. 2021 Feb 25;57(2):2000124. PMID: 32631835; PMCID: PMC7905834. doi: 10.1183/13993003.00124-2020
21. McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schüler R, Wiklund I, Peacock A; IRB information for the 5 clinical sites. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res. 2016 Jun 14;17(1):72. PMID: 27301413; PMCID: PMC4908719. doi: 10.1186/s12931-016-0388-6
22. Chin KM, gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. Chest. 2018 Oct;154(4):848-861. Epub 2018 Apr 26. doi: 10.1016/j.chest.2018.04.027
23. Frantz RP, Chin KM, Zhao C, Flynn M, Badesch D. Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting. Pulm Circ. 2020 May 14;10(2):2045894020923957. PMID: 32489644; PMCID: PMC7238840. doi: 10.1177/2045894020923957
Review
For citations:
Nikolaeva E.A., Valieva Z.S., Martynyuk T.V. Quality of life аssessment in patients with pulmonary arterial hypertension. Systemic Hypertension. 2024;21(3):41-46. (In Russ.) https://doi.org/10.38109/2075-082X-2024-3-41-46
Views:
138
Email this article 